Eli Lilly’s Obesity Pill Shows Promising Weight Loss in New Results
In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 percent of their body weight.
States Are Moving to Protect Access to Vaccines
As federal vaccine policy shifts under US health secretary Robert F. Kennedy Jr., lawmakers are looking to give state-level public health officials authority to ignore federal recommendations.
Florida Is Now a Haven for Unproven Stem-Cell Treatments
In a measure that flouts the FDA, Florida says doctors can give unapproved stem-cell therapies for wound care, pain management, or orthopedic purposes.
There’s Neuralink—and There’s the Mind-Reading Company That Might Surpass It
Unlike Elon Musk's brain-computer interface, Synchron's doesn't require open-skull surgery, and it has an OpenAI chatbot baked in.
Can US Measles Outbreaks Be Stopped?
The US almost lost its measles elimination status once. Lessons from that episode suggest it will be more difficult to avoid doing so now.
Trump’s ‘Big Beautiful Bill’ Would Leave Millions Without Health Insurance
Nearly 12 million people could lose health care coverage if the bill gets passed and signed by Trump, while hospitals would be hit hard by Medicaid cuts.
Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.
US Supreme Court Upholds Tennessee’s Ban on Gender-Affirming Care for Minors
In United States v. Skrmetti, the Supreme Court ruled that Tennessee’s ban on gender-affirming care for minors was not unconstitutional—the first case of its kind on which the court has ruled.
A New Obesity Pill May Burn Fat Without Suppressing Appetite
An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.
Congress Demands Answers on Data Privacy Ahead of 23andMe Sale
House Democrats sent letters to the potential buyers of the genetic testing company, asking how they plan to protect customer genetic data under a change of ownership.